ACR 132 is a concurrent resolution designating February 28, 2026, as Rare Disease Day in California. The resolution states that rare diseases affect fewer than 200,000 people per disease in the United States, but collectively impact millions of patients, including many children, and often involve serious or life-threatening conditions. It emphasizes the challenges patients and families face in obtaining accurate diagnoses, finding specialists, and affording limited treatment options.
The measure also highlights broader policy and research efforts related to rare diseases, including the federal Orphan Drug Act, FDA programs to accelerate rare disease cures, and California’s own Jacqueline Marie Zbur Rare Disease Advisory Council. It recognizes the role of California’s life sciences sector and research institutions in developing rare disease therapies, and it frames Rare Disease Day as part of a global awareness effort observed in more than 100 countries.
Impact
As a concurrent resolution, ACR 132 does not change substantive state law or create regulatory requirements. Its legal effect is to formally designate February 28, 2026, as Rare Disease Day and to express the Legislature’s support for improving awareness, early and accurate diagnosis, and the development of treatments, diagnostics, and cures for rare diseases and disorders. The resolution also reinforces existing state and federal rare disease policy efforts by acknowledging California’s advisory council and the role of FDA and NIH research initiatives.
Sentiment
The sentiment around the bill appears strongly supportive and noncontroversial. The resolution passed with unanimous votes in the recorded actions, including a 6-0 vote to move it to third reading and a 34-0 special consent vote. The text itself is celebratory and advocacy-oriented, presenting Rare Disease Day as a way to raise awareness and offer hope to patients and families affected by rare conditions.
Contention
There is little to no evident contention in the available record. No committee transcript objections are provided, and the votes were unanimous. The only substantive policy themes are broad support for rare disease awareness, diagnosis, and treatment development, which are presented as consensus goals rather than disputed issues. Any implied policy concern is the ongoing challenge of limited treatments and access to specialized care, but the resolution does not propose a contested remedy or funding mechanism.